MM
Michele Marie Miller
Executive Vice President, General Counsel, and Corporate Secretary
OraSure TechnologiesTherapeutic Areas
OraSure Technologies Pipeline
| Drug | Indication | Phase |
|---|---|---|
| OraQuick® HCV Rapid Antibody Test | Hepatitis C (HCV) infection | Approved |
| OraQuick® HIV Self-Test | Human Immunodeficiency Virus (HIV) infection | Approved |
| OraQuick® HIV 1/2 Rapid Antibody Test | Human Immunodeficiency Virus (HIV) infection | Approved |
| InteliSwab® COVID-19 Rapid Test | SARS-CoV-2 infection (COVID-19) | Approved |
| Oral Fluid Collection Device | Sample collection for molecular testing | Approved |
| Intercept® Oral Fluid Drug Test | Workplace drug testing | Approved |
| OraSure® HIV-1 | HIV-1 incidence testing | Approved |
Leadership Team at OraSure Technologies
SS
Stephen S. Tang
President, Chief Executive Officer, and Chairman of the Board
KJ
Kenneth J. McGrath
Executive Vice President and Chief Financial Officer
NJ
Nancy J. Gagliano
Chief Medical Officer
KW
Kathleen Weber
Senior Vice President, Global Commercial Operations
RJ
Robert J. Shovlin
Senior Vice President, Operations
CH
Chad H. Fallis
Senior Vice President, Corporate Development & Strategy
CA
Carol A. DiSanto
Board Member
MC
Michael Celano
Board Member
JH
James H. Skogsbergh
Board Member
SM
Sharon M. O'Kane
Board Member